News · 26 weeks176-24%
2025-12-282026-06-21
Mix8490d
- SEC Filings76(90%)
- Other8(10%)
Latest news
25 items- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- PRUtebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)First and only oral carbapenem antibiotic approved in the US Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment1 More than 3 million cases of cUTIs are treated annually in the US2 with up to a third of patients impacted by resistant infections3 GSK plc (LSE/NYSE:GSK) and Spero Therapeutics (NASDAQ:SPRO) today announced that the US Food and Drug Administration (FDA) has approved Utebzi, an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritisi, caused by certain susceptible pathogensii in adult patients who have limited or no alternative oral treatment options. This is the first and o
- PRUtebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)First and only oral carbapenem antibiotic approved in the USApproval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatmentiMore than 3 million cases of cUTIs are treated annually in the US with a third of patients impacted by resistant infectionsii,iii CAMBRIDGE, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO) and GSK plc (LSE/NYSE:GSK) today announced that the US Food and Drug Administration (FDA) has approved Utebzi, an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritis1, caused by certain susceptible pathogens2 in adult patients who have limited or no alternative or
- SECSEC Form 11-K filed by GSK plc11-K - GSK plc (0001131399) (Filer)
- SECSEC Form 11-K filed by GSK plc11-K - GSK plc (0001131399) (Filer)
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- PRCancer's Toughest Targets Are Drawing Wall Street's Attention as Oncology Innovation AcceleratesDENVER, June 09, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Artificial intelligence continues to dominate healthcare headlines, but another transformative story is quietly unfolding across biotechnology: the race to develop more effective treatments for some of the deadliest forms of cancer. From precision oncology and targeted therapies to next-generation approaches designed to overcome treatment resistance, a new wave of innovation is emerging that could reshape cancer care over the next decade. One area drawing increasing attention is neuro-oncology, particularly therapies targeting glioblastoma multiforme (GBM) and other aggressive brain cancers. Despite decades of research an
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- SECSEC Form SD filed by GSK plcSD - GSK plc (0001131399) (Filer)
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
- SECSEC Form 6-K filed by GSK plc6-K - GSK plc (0001131399) (Filer)
GSK FAQ
7 questionsWhat does GSK plc do?
GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system...Where does GSK stock trade?
GSK plc (GSK) is listed on NYSE.What sector and industry is GSK in?
GSK plc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did GSK plc go public?
GSK plc (GSK) completed its IPO in 2022.What are analysts saying about GSK?
GSK plc has had 8 recent analyst actions on file. The most recent action was from Citigroup: Neutral on 2026-01-27. Recent price targets range from $3525.00 to $3950.00.What companies are similar to GSK?
Notable peers in the same industry include JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), NVS (Novartis AG), SNY (Sanofi). Compare GSK side-by-side with any of them on Quantisnow.How can I track GSK on Quantisnow?
Quantisnow aggregates GSK plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GSK to receive live email and push alerts on every new disclosure.